C188-9 compound

a STAT3 inhibitor with antineoplastic activity; structure in first source

Also Known As:

N-(4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl)-4-methoxybenzenesulfonamide; STAT3 inhibitor TTI-101; TTI-101

Networked: 6 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tweardy, David J: 3 articles (10/2021 - 01/2020)
2.	Kasembeli, Moses M: 2 articles (10/2021 - 01/2020)
3.	Adams, Clydell: 1 article (10/2021)
4.	Edralin, Jules: 1 article (10/2021)
5.	Heijnen, Cobi J: 1 article (10/2021)
6.	Kavelaars, Annemieke: 1 article (10/2021)
7.	Ma, Jiacheng: 1 article (10/2021)
8.	Singhmar, Pooja: 1 article (10/2021)
9.	Tang, Yongfu: 1 article (10/2021)
10.	Bottazzi, Maria Elena: 1 article (01/2021)

Related Diseases

1.	Inflammation (Inflammations) 05/30/2023 - "Importantly, TTI-101 treatment of DSS-administered WT mice led to complete attenuation of each of the clinical manifestations and also led to increased apoptosis of colonic CD4+ T cells, reduced colon infiltration with IL-17-producing cells, and down-modulation of colon mRNA levels of STAT3-upregulated genes involved in inflammation, apoptosis resistance, and colorectal cancer metastases. " 01/01/2021 - "By the end of treatment, STAT3 inhibition with TTI-101 eliminated cardiac fibrosis and fibrosis biomarkers but increased cardiac inflammation; serum levels of interleukin-6 (IL-6), and IFN-γ; cardiac gene expression of STAT1 and nuclear factor-κB (NF-κB); and upregulation of IL-6 and Type I and Type II IFN responses. "
2.	Fibrosis (Cirrhosis) 01/01/2021 - "By the end of treatment, STAT3 inhibition with TTI-101 eliminated cardiac fibrosis and fibrosis biomarkers but increased cardiac inflammation; serum levels of interleukin-6 (IL-6), and IFN-γ; cardiac gene expression of STAT1 and nuclear factor-κB (NF-κB); and upregulation of IL-6 and Type I and Type II IFN responses. "
3.	Neoplasms (Cancer) 01/01/2022 - "TTI-101 is currently being evaluated in a Phase 1 study to determine safety and tolerability in addition to pharmacodynamic effects and efficacy in patients with advanced solid tumors." 10/01/2021 - "TTI-101 has shown target engagement, no toxicity, and evidence of clinical benefit in a Phase I study in patients with solid tumors. " 10/01/2021 - "Thus, in addition to its direct anti-tumor effect, TTI-101 may be of benefit when administered to cancer patients at risk of developing chemotherapy-induced peripheral neuropathy (CIPN)."
4.	Colitis 05/30/2023 - "We also examined the effect of TTI-101 on these endpoints in DSS-induced colitis in WT mice. " 05/30/2023 - "In the current study, we determined the contribution of STAT3 to IBD across all tissues by examining DSS-induced colitis in mice that express only STAT3α and in mice treated with TTI-101, a direct small-molecule inhibitor of both isoforms of STAT3. "
5.	Chronic Renal Insufficiency 01/01/2020 - "Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease."

Related Drugs and Biologics

1.	Interleukin-6 (Interleukin 6)
2.	Biomarkers (Surrogate Marker)
3.	Protein Isoforms (Isoforms)
4.	Messenger RNA (mRNA)
5.	benzonidazole (benznidazole)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)